TY - JOUR
T1 - Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS tat-based vaccines
AU - Titti, Fausto
AU - Maggiorella, Maria T.
AU - Ferrantelli, Flavia
AU - Sernicola, Leonardo
AU - Bellino, Stefania
AU - Collacchi, Barbara
AU - Belasio, Emanuele Fanales
AU - Moretti, Sonia
AU - Cossut, Maria Rosaria Pavone
AU - Belli, Roberto
AU - Olivieri, Erika
AU - Farcomeni, Stefania
AU - Compagnoni, Daniela
AU - Michelini, Zuleika
AU - Sabbatucci, Michela
AU - Sparnacci, Katia
AU - Tondelli, Luisa
AU - Laus, Michele
AU - Cafaro, Aurelio
AU - Caputo, Antonella
AU - Ensoli, Barbara
N1 - Publisher Copyright:
Copyright © 2014 Titti et al.
PY - 2014/10/30
Y1 - 2014/10/30
N2 - Here we describe a prime-boost regimen of vaccination in Macaca fascicularis that combines priming with novel anionic microspheres designed to deliver the biologically active HIV-1 Tat protein and boosting with Tat in Alum. This regimen of immunization modulated the IgG subclass profile and elicited a balanced Th1-Th2 type of humoral and cellular responses. Remarkably, following intravenous challenge with SHIV89.6Pcy243, vaccinees significantly blunted acute viremia, as compared to control monkeys, and this control was associated with significantly lower CD4+ T cell depletion rate during the acute phase of infection and higher ability to resume the CD4+ T cell counts in the post-acute and chronic phases of infection. The long lasting control of viremia was associated with the persistence of high titers anti-Tat antibodies whose profile clearly distinguished vaccinees in controllers and viremics. Controllers, as opposed to vaccinated and viremic cynos, exhibited significantly higher pre-challenge antibody responses to peptides spanning the glutamine-rich and the RGDintegrinbinding regions of Tat. Finally, among vaccinees, titers of anti-Tat IgG1, IgG3 and IgG4 subclasses had a significant association with control of viremia in the acute and post-acute phases of infection. Altogether these findings indicate that the Tat/H1D/Alum regimen of immunization holds promise for next generation vaccines with Tat protein or other proteins for which maintenance of the native conformation and activity are critical for optimal immunogenicity. Our results also provide novel information on the role of anti-Tat responses in the prevention of HIV pathogenesis and for the design of new vaccine candidates.
AB - Here we describe a prime-boost regimen of vaccination in Macaca fascicularis that combines priming with novel anionic microspheres designed to deliver the biologically active HIV-1 Tat protein and boosting with Tat in Alum. This regimen of immunization modulated the IgG subclass profile and elicited a balanced Th1-Th2 type of humoral and cellular responses. Remarkably, following intravenous challenge with SHIV89.6Pcy243, vaccinees significantly blunted acute viremia, as compared to control monkeys, and this control was associated with significantly lower CD4+ T cell depletion rate during the acute phase of infection and higher ability to resume the CD4+ T cell counts in the post-acute and chronic phases of infection. The long lasting control of viremia was associated with the persistence of high titers anti-Tat antibodies whose profile clearly distinguished vaccinees in controllers and viremics. Controllers, as opposed to vaccinated and viremic cynos, exhibited significantly higher pre-challenge antibody responses to peptides spanning the glutamine-rich and the RGDintegrinbinding regions of Tat. Finally, among vaccinees, titers of anti-Tat IgG1, IgG3 and IgG4 subclasses had a significant association with control of viremia in the acute and post-acute phases of infection. Altogether these findings indicate that the Tat/H1D/Alum regimen of immunization holds promise for next generation vaccines with Tat protein or other proteins for which maintenance of the native conformation and activity are critical for optimal immunogenicity. Our results also provide novel information on the role of anti-Tat responses in the prevention of HIV pathogenesis and for the design of new vaccine candidates.
UR - http://www.scopus.com/inward/record.url?scp=84910091901&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0111360
DO - 10.1371/journal.pone.0111360
M3 - Article
SN - 1932-6203
VL - 9
JO - PLoS ONE
JF - PLoS ONE
IS - 10
M1 - e111360
ER -